Fig. 6: NONO and RPLP0 promote tumor radioresistance.
Knocking out of NONO sensitized tumor cells to irradiation. Twenty-four hours after seeding, HCT116 (5000 cells) (A) and U2OS (3000 cells) (B) were irradiated with indicated dose and cultured for 10 days. Cells were fixed and stained with 0.2% crystal violet. n = 3 independent experiments. C Knocking out of NONO sensitized xenografts to radiation in vivo. Ten days after MC38 cells (2 × 105) injection, tumors were irradiated with or without 10 Gy (day 0) X-ray and observed for 13 days. RT., Radiotherapy; Ctrl., Control. n = 6 xenografts. D The NONO and RPLP0 levels in biopsy were analyzed by IHC. n = 15 (TRG0), 11 (TRG1), 49 (TRG2), or 22 (TRG3) specimens of rectal cancer. E The NONO and RPLP0 levels in operation specimens were analyzed by IHC. n = 45 (TRG0&1) or 37 (TRG2&3) specimens of rectal cancer. F, G The mRNA and protein level of NONO and RPLP0 were examined in rectal cancer tissues. The mRNA and protein level of NONO and RPLP0 in 30 pairs of normal and rectal cancer tissues were examined by qPCR and western blotting analysis. n = 30 pairs of normal and rectal cancer tissues. H The association of NONO and RPLP0 was examined with Duolink PLA assay in rectal cancer biopsy species. IgGs was used as a negative control. (Top) Scale bars, 25 μm; (Bottom) Scale bars, 10 μm. antibodies: anti-NONO and anti-RPLP0 antibodies; IgGs: immunoglobulin G from mouse and rabbit. I NONO-RPLP0 fusion protein promotes radioresistance. n = 3 biological replicates. *, P < 0.05; **; P < 0.01, ***; P < 0.001.
